Core Viewpoint - The company, Shandong Pharmaceutical Glass Co., Ltd., is utilizing idle raised funds to invest in wealth management products to enhance the efficiency of fund usage and generate additional returns for the company and its shareholders [3][11]. Group 1: Investment Overview - The company has entrusted China Bank with a total of RMB 14,280 million and RMB 13,720 million for wealth management products [1]. - The investment products are structured deposits with terms of 85 days and 86 days [7]. - The company has already used RMB 75,000 million of raised funds for wealth management products, remaining within the authorized limit set by the shareholders' meeting [4]. Group 2: Purpose and Source of Funds - The purpose of the investment is to improve the efficiency of idle raised funds while ensuring the safety and liquidity of the funds [3]. - The source of funds for this investment is the company's idle raised funds [5]. Group 3: Impact on Fund Projects - The investment in wealth management products will not affect the implementation progress of the fundraising projects and will not change the intended use of the raised funds [7][11]. - This investment is expected to enhance the efficiency of fund usage and provide returns for the company and its shareholders, particularly benefiting minority shareholders [11]. Group 4: Decision-Making Process - The decision to use idle raised funds for wealth management products was approved in meetings held on April 23, 2025, and May 16, 2025 [11]. - The company has been authorized to use up to RMB 800 million of idle raised funds for safe and liquid wealth management products with a maturity of no more than 12 months [11].